Kerwar S S
Am J Med. 1983 Oct 31;75(4B):62-9. doi: 10.1016/0002-9343(83)90330-3.
Fenbufen (Cinopal) is an orally active nonsteroidal anti-inflammatory drug with analgesic and antipyretic activity. Like clinically used nonsteroidal anti-inflammatory drugs, it shows activity in a wide spectrum of laboratory tests in mice, rats, guinea pigs, and dogs. Fenbufen has a long duration of anti-inflammatory and analgesic activity. Mechanistic studies indicate that fenbufen has no intrinsic effect on cyclooxygenase activity, whereas its major metabolite, biphenylacetic acid, is a potent inhibitor of prostaglandin synthesis. These observations indicate that fenbufen is a pro-drug and account for its low ulcerogenic potential. Anti-inflammatory pro-drugs that are readily metabolized to the biologically active molecule are expected to retain a favorable anti-inflammatory to ulcerogenic ratio because the gastrointestinal tract is not exposed to a large concentration of the active molecule. Comparative studies in the type II collagen arthritis model indicate that the anti-inflammatory properties of fenbufen are more potent than those of a second nonsteroidal anti-inflammatory drug, sulindac.
芬布芬(Cinopal)是一种具有口服活性的非甾体抗炎药,具有镇痛和解热作用。与临床使用的非甾体抗炎药一样,它在小鼠、大鼠、豚鼠和狗的多种实验室测试中均表现出活性。芬布芬具有长效的抗炎和镇痛活性。机制研究表明,芬布芬对环氧化酶活性无内在影响,而其主要代谢产物联苯乙酸是前列腺素合成的有效抑制剂。这些观察结果表明芬布芬是一种前体药物,这也解释了其较低的致溃疡潜力。易于代谢为生物活性分子的抗炎前体药物有望保持良好的抗炎与致溃疡比率,因为胃肠道不会接触到高浓度的活性分子。在II型胶原性关节炎模型中的比较研究表明,芬布芬的抗炎特性比另一种非甾体抗炎药舒林酸更强。